Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Assertio Therapeutics (ASRT) Stock Price & Analysis
825 Followers
ASRT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.86 - $7.00
Previous Close$5.78
Volume196.72K
Average Volume (3M)1.88M
Market Cap
$332.92M
Enterprise Value$323.18M
Total Cash (Recent Filing)$64.94M
Total Debt (Recent Filing)$66.87M
Price to Earnings (P/E)3.3
Beta1.08
Next Earnings
May 04, 2023EPS Estimate
$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.75
Shares Outstanding48,293,613
10 Day Avg. Volume1,840,143
30 Day Avg. Volume1,883,551
Standard Deviation0.27
R-Squared0.00567
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-4.22
Price to Sales (P/S)2.26
Price to Cash Flow (P/CF)4.30
P/FCF Ratio6.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.07
Enterprise Value/Gross Profit2.35
Enterprise Value/Ebitda4.47
Forecast
1Y Price Target
$8.50Price Target Upside41.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Assertio Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ASRT FAQ
What was Assertio Therapeutics Inc’s price range in the past 12 months?
Assertio Therapeutics Inc lowest stock price was $1.86 and its highest was $7.00 in the past 12 months.
What is Assertio Therapeutics Inc’s market cap?
Currently, no data Available
When is Assertio Therapeutics Inc’s upcoming earnings report date?
Assertio Therapeutics Inc’s upcoming earnings report date is May 04, 2023 which is in 44 days.
How were Assertio Therapeutics Inc’s earnings last quarter?
Assertio Therapeutics Inc released its earnings results on Mar 08, 2023. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.482 by -$0.162.
Is Assertio Therapeutics Inc overvalued?
According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued.
Does Assertio Therapeutics Inc pay dividends?
Assertio Therapeutics Inc does not currently pay dividends.
What is Assertio Therapeutics Inc’s EPS estimate?
Assertio Therapeutics Inc’s EPS estimate is $0.17.
How many shares outstanding does Assertio Therapeutics Inc have?
Assertio Therapeutics Inc has 55,578,545 shares outstanding.
What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?
Assertio Therapeutics Inc reported an EPS of $0.32 in its last earnings report, missing expectations of $0.482. Following the earnings report the stock price went up 11.745%.
Which hedge fund is a major shareholder of Assertio Therapeutics Inc?
Among the largest hedge funds holding Assertio Therapeutics Inc’s share is First Eagle Investment Management LLC. It holds Assertio Therapeutics Inc’s shares valued at 3M.
---
Assertio Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (41.90% Upside)
$8.50 (41.90% Upside)
Blogger Sentiment
Bullish
ASRT Sentiment 91%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 201.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.2%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
111.72%
12-Months-Change
Fundamentals
Return on Equity
66.82%
Trailing 12-Months
Asset Growth
26.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Assertio Therapeutics Inc
Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
---
---